Q1 2024 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2024-05-06 · accession 0001104659-24-057096
$1.08B
Reported value
16
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $227.7M | 21.0% | 8,020,136 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $216.2M | 19.9% | 5,377,362 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $142.4M | 13.1% | 2,287,233 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $106.2M | 9.80% | 6,430,257 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $103.0M | 9.50% | 10,907,859 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $100.7M | 9.30% | 1,119,292 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $60.3M | 5.57% | 2,039,249 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $35.6M | 3.29% | 2,092,106 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $33.7M | 3.11% | 8,279,484 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $19.9M | 1.84% | 5,836,874 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $17.1M | 1.58% | 2,098,300 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $7.1M | 0.66% | 5,018,178 | Common | SOLE |
| 05455M100 | — | AvroBio, Inc. | $5.8M | 0.54% | 4,541,381 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $5.6M | 0.52% | 186,979 | Common | SOLE |
| 98422T100 | — | Xilio Therapeutics, Inc. | $1.1M | 0.10% | 992,912 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $1.0M | 0.10% | 607,613 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.